title: Brimonidine tartrate for the treatment of facial flushing and erythema in rosacea.
abstract: Rosacea is a chronic inflammatory dermatologic condition that can often be disfiguring with significant negative impact on patients' quality of life. Sanrosa (brimonidine tartate) is a novel therapeutic agent targeting the facial flushing and erythema of rosacea through its α₂ adrenergic receptor agonist activity. The goal of this article is to discuss current treatment options for rosacea and the properties of brimonidine tartate as well as the evidence surrounding its efficacy and safety profile.
authors.affiliation: David Geffen School of Medicine at the University of California, Los Angeles, CA, USA.
authors.forename: Lana X
authors.initials: LX
authors.lastname: Tong
authors.forename: Angela Yen
authors.initials: AY
authors.lastname: Moore
mesh_terms: D058647:Adrenergic alpha-2 Receptor Agonists / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use; D000818:Animals; D000068438:Brimonidine Tartrate; D004890:Erythema / Q000188:drug therapy*; D006801:Humans; D011788:Quality of Life; D011810:Quinoxalines / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D012393:Rosacea / Q000188:drug therapy* / Q000473:pathology; D016896:Treatment Outcome
chemical_list: D058647:Adrenergic alpha-2 Receptor Agonists; D011810:Quinoxalines; D000068438:Brimonidine Tartrate
keywords: brimonidine; brimonidine tartrate; facial erythema; rosacea; rosacea treatment; sansrosa